ArticleScientific reports2025
The diagnostic value of LncRNA NEAT1 targeting miR-129-5p in pancreatic cancer patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long Non-Coding RNAs in Human Disease: An Overview of Biogenesis, Molecular Mechanism and Therapeutic Opportunities.Current issues in molecular biology · 2026Review
- Role of autophagy‑modulating long non‑coding RNAs in tumor radioresistance (Review).Oncology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early pancreatic cancer (PC) identification and management has gained much clinical and research attention. Recent reports have demonstrated the important function of circulating noncoding RNAs (ncRNAs) in the diagnosis and prognosis of malignancies. However, the clinical value of serum ncRNAs in PC has not been fully clarified. Hence, we investigated serum levels of long-ncRNA NEAT1 and miR-129-5p in PC cases, exploring their relationship with related targets BCL2 and TGF-β1. Serum NEAT1 and miR-129-5p levels were evaluated in 60 treatment-naïve PC cases and 30 apparent healthy individuals by RT-PCR. Besides, serum TGF-β1 and BCL2 levels were measured by ELISA, whereas CA19-9 and CEA were measured utilizing the chemiluminescence technique. We demonstrated that serum NEAT1, BCL2, and TGF-β1 levels were significantly upregulated, whereas serum levels of miR-129-5p were markedly reduced in PC cases compared to controls. miR-129-5p had a higher diagnostic value for PC than NEAT1, with specificity, sensitivity, and AUC of 100%, 95%, and 0.96 versus 93.3%, 83.3%, and 0.89, respectively. Moreover, miR-129-5p had a higher AUC than CA19-9 and CEA. Additionally, serum miR-129-5p was significantly downregulated in PC cases with T3 or T4 stages compared to those with T2 stage & negatively correlated with NEAT1, BCL2, and TGF-β1, whereas NEAT1 was notably positively correlated with BCL2 and TGF-β1. Collectively, serum NEAT1 and miR-129-5p could be beneficial biomarkers for the detection of PC. Also, our findings accentuate the correlation between NEAT1, miR-129-5p, BCL2, and TGF-β1 and provide PC therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.